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Background: A new human myeloma cell line, MMLAL, was established from the myelomatous pleural effusion of
a 73-year-old Chinese patient suffering from symptomatic International stage III IgG/lambda myeloma. After a brief
period of complete remission, he developed aggressive systemic relapse complicated by malignant pleural effusion
with exclusive plasma cell infiltration. His disease remained chemo-refractory, and died six months after relapse.
Methods: Purified mononuclear cells from the pleural effusion of the patient were cultured in the presence of IL-6.
Continually growing cells were characterized by morphological, immunophenotypic, cytogenetic, fluorescence in
situ hybridization (FISH) and TP53 mutation analyses. Cell proliferation was measured and compared with other
myeloma cell lines by cell counting at day 3, 6, 9, and 12. Drug resistance against bortezomib, a proteasome inhibitor
approved as a frontline chemotherapy for eligible myeloma patients, was evaluated and compared with other myeloma
cell lines by MTT assay.
Results: Immunophenotypic analysis of the myeloma cells confirmed strong expression of plasma cell markers CD38
and CD138 but not T-cell or natural killer-cell marker CD56. Cytogenetic analysis of the myeloma cells showed a
hypodiploid composite karyotype including loss of chromosome 13 and 17 or deletion of the short arm of chromosome
17, i.e. del(17p), in the form of isochromosome 17q10. FISH confirmed a hypodiploid karyotype with TP53 deletion but
absence of t(4;14). Sequencing analysis of the TP53 gene indicated absence of mutation. Cell counting revealed that the
maximum viable cell density was about 2.5 X 106 cells/ml. Upon bortezomib treatment, MTT assay reported an IC50 of
72.17nM, suggesting a strong bortezomib resistance.
Conclusion: A hypodiploid with loss of chromosome 13 and loss or del(17p) human myeloma cell line, MMLAL, was
established from the pleural effusion of a Chinese myeloma patient.
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Multiple myeloma is a cancer derived from malignant
transformation of plasma cells [1]. It ranks the second
or third most common hematological malignancy in the
world. Interestingly, the incidence of myeloma in Western
countries appears to be higher than that in Asian coun-
tries [2]. In the United States, the average incidence of
myeloma from 2005–2009 was 5.8/100,000 [3]. By con-
trast, it was much lower in the Far East that it was 1.9/
100,000 in Hong Kong [4], and 1.4/100,000 in Korea [5].
Clinically, myeloma arises from neoplastic transform-
ation of a post-germinal center B cell, which will next* Correspondence: jcschim@hku.hk
1Department of Medicine, Queen Mary Hospital, University of Hong Kong,
Room 419, Block K Pokfulam Road, Hong Kong, Hong Kong
Full list of author information is available at the end of the article
© 2013 Wong et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhome to the bone marrow and manifest an asymptom-
atic condition known as monoclonal gammopathy of
undetermined significance (MGUS). MGUS will progress
into symptomatic myeloma at a rate of 1% per year, as-
sociated with emergence of key end-organ damages,
including hypercalcemia, renal failure, anemia and bone
lesions. At the terminal stage of the disease, myeloma
cells will become independent of the bone marrow
stroma, resulting in the development of extramedullary
myeloma such as plasma cell leukemia [6,7].
Genetically, myeloma is characterized by universal up-
regulation of cyclin D1, D2 or D3. However, the patho-
genesis of myeloma is complicated by variable gains and
losses of chromosomes that further subdivided the dis-
ease into non-hyperdiploid and hyperdiploid myeloma.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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half of the disease, is characterized by strong associ-
ation with primary immunoglobulin heavy (IgH) chain
translocations, such as t(11;14)(q13;q32), t(4;14)(p16.3;
q32), t(14;16)(q32;q23), t(6;14)(p21;q32) or t(14;20)
(q32;q11), resulting in direct or indirect upregulation
of cyclin D1, D2 or D3. On the other hand, hyperdiploid
myeloma, which constitutes the other half of the disease,
is usually associated with trisomies of odd-numbered
chromosomes (except chr13), in particular trisomies of
chr11 leads to direct upregulation of cyclin D1 [6,7].
Currently, majority of human myeloma cell lines was
derived from extramedullary myeloma disease, including
sacral plasmacytoma, circulating plasma cells, or myelo-
matous pleural effusion like our case [8]. However, there
is only a few human myeloma cell lines derived from
Chinese patients [9,10]. Herein, we report the establish-
ment and characterization of a new human myeloma cell
line, MMLAL, derived from a Chinese patient.
Results
Establishment of MMLAL
MMLAL was established from purified mononuclear
cells, which were harvested from the pleural effusion of
a Chinese myeloma patient suffering from IgG/lambda
myeloma, who relapsed after a brief period of complete
remission and terminated with chemo-refractory mye-
lomatous pleural effusion (Figure 1). Cells were first
cultured in a medium mixture of 40% DMEM+ 40%Figure 1 Radiographic image of the myeloma patient. Chest
X-ray showed pleural masses after drainage of the myelomatous
pleural effusion (arrows).IMDM, supplemented with rich fetal bovine serum and
IL-6, an important cytokine that support myeloma cell
growth in the bone marrow microenvironment. Initially,
the total number of mononuclear cells decreased gradually
and remained unchanged thereafter. Medium was changed
in every 3 or 4 days. After 4 months, the total number of
cells started to increase. The cells were cultured continu-
ously for more than 12 months and gradually maintained
in the absence of IL-6.
Morphology of MMLAL cells
The MMLAL cells mainly grew in suspension as clusters
with a small proportion in single cells. Microphotograph
of a cytospin preparation of the MMLAL cells is shown
in Figure 2. The MMLAL cells were characterized by a
relatively low nuclear-to-cytoplasmic ratio, eccentrically
located large nuclei which are oval to convoluted in
shape, prominent nucleoli, and abundant deep basophilic
cytoplasm with prominent perinuclear hof.
Immunophenotypic analysis
Immunophenotypic analysis showed that the MMLAL
cells were positive for plasma cell markers CD38 and
CD138 (Figure 3A and B), and IgG lambda (Figure 3C
and D), but negative for T- or NK-cell marker CD56.
Metaphase cytogenetics
Metaphase karyotyping of the MMLAL cells indicated a
hypodiploid composite karyotype (chromosome number
31–46) with loss of multiple chromosomes, including
chromosomes 13, 17 and 21 (Figure 4; Tables 1 and 2).
Moreover, recurrent IgH translocations frequently found
in myeloma that involve 14q32, such as t(11;14), t(14;16), t
(6;14) or t(14;20), were not detected.
Interphase FISH
FISH analyses showed that the MMLAL cells were hypo-
diploid with TP53 deletion (Figure 5). Moreover, FISH
for t(4;14) was absent, which is cryptic and hence might
be missed by metaphase cytogenetics.
TP53 mutation analysis
No TP53 mutation was found in bidirectional sequen-
cing analysis of exons 4–10 of TP53 of the MMLAL
cells (Table 2).
Cell growth
Counting of viable cells demonstrated that the MMLAL
cells grew continuously from 1 X 106 to 2.5 X 106 cells/
ml in 6 days, and reached a growth plateau (Figure 6A).
It was in contrast to other commonly used myeloma cell
lines, including KMS-12-PE, NCI-H929, and JJN-3,
which might reach at a higher cell density of > 3.5 X 106
cells/ml in 12 days.
Figure 2 Morphology of the MMLAL cells. MMLAL cells were visualized with Wright’s staining, original magnification x 1000. Cells were
predominantly mononuclear with eccentrically located large nuclei of oval to convoluted in shape, with condensed chromatin, prominent
nucleoli, and abundant basophilic cytoplasm, with perinuclear hof.
Figure 3 Immunophenotypic analyses of the MMLAL cells. The MMLAL cells were stained with A) anti-CD38, B) anti-CD138, C) anti-IgG,
lambda, and D) anti-IgG, kappa. Flow cytometric analyses indicated that the MMLAL cells showed high expression of plasma cell markers CD38
and CD138, and IgG lambda light chain restriction.
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Figure 4 Representative karyotype of the MMLAL cells: 45, XY, i(17)(q10), -21.
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MTT assays indicated that the MMLAL cells responded
to bortezomib treatment with an IC50 of 72.17nM,
whereas other commonly used myeloma cell lines NCI-
H929, KMS-12-PE, and JJN-3 showed an IC50 of 2.71nM,
8.55nM, and 89.39nM respectively (Figure 6B).
Discussion
We reported the establishment of a new human mye-
loma cell line, MMLAL, which was derived from the
pleural effusion of a Chinese patient. Based on con-
ventional karyotyping and interphase FISH analyses,
MMLAL was characterized by a hypodiploid composite
karyotype, loss of chromosome 13, loss of chromosome
17 or del(17p), with the absence of primary IgH trans-
location and TP53 mutation.
Review of the commonly used myeloma cell lines in
our laboratory together with the other two Chinese-
derived myeloma cell lines, MM17 and CZ-1, most of
them are hypodiploid (MM17, KMS-12-PE, NCI-H929,
U-266), which are the same as the MMLAL, whereas the
others are near-tetraploid (LP-1 and OPM-2), near-diploid
(MOLP-8), or hyperdiploid (CZ-1 and RPMI-8226).
Despite the frequent association of hypodiploid mye-
loma with primary IgH translocations, MMLAL did not
display any of the primary IgH translocations by conven-
tional metaphase cytogenetics or t(4;14) by interphaseTable 1 MMLAL karyotype
Cell line Karyotype
MMLAL 31 ~ 46,XY,-Y[5],-4[3],-8[3],-10[3],-13FISH, which is cryptic and often missed by metaphase
karyotyping [13-15]. Although a comprehensive FISH
study for all known IgH translocations has not been per-
formed, recurrent IgH translocations frequently found in
myeloma that involve 14q32, such as t(11;14), t(14;16), t
(6;14) or t(14;20), were not detected based in metaphase
cytogenetic analysis. On the other hand, t(4;14), a cryptic
translocation not detectable by metaphase cytogenetic
study, has been confirmed to be negative by interphase
FISH in our study. This contrasted with the presence of
primary IgH translocations in other hypodiploid myeloma
cell lines, including t(11;14) in KMS-12-PE, t(4;14) in
NCI-H929, and t(8;14) in MM17 (Table 2). Of the other
common numerical karyotypic abnormalities, MMLAL
harbored concomitant loss or del(13) and del(17p). In-
deed, all of these hypodiploid myeloma cell lines carry del
(13). By interphase FISH, 17p loss in the MMLAL was
found due to loss of the whole chromosome 17 in some
cells and isochromosome 17q10 in other cells, leading to
monoallelic loss of TP53. Hence, the MMLAL was found
similar to most of the hypodiploid myeloma cell lines,
which possesses either del(17p) or TP53 mutation, con-
firming that del(17p) or inactivation of TP53 is a frequent
and important terminal event of the disease.
The MMLAL showed a unique growth characteristic
of having a maximum cell density of 2.5 X 106 cells/ml,
as compared with other commonly used myeloma cell[5],-14[4],-15[3],-17[11],i(17)(q10)[2],-19[4],-20[7],-21[9],-22[6][cp19]/46,XY[5]
Table 2 Characteristics of the MMLAL versus other Chinese-derived (MM17 and CZ-1) and several commonly used human myeloma cell lines
Cell line MMLAL MM17 KMS-12-PE NCI-H929 U-266 LP-1 OPM-2 MOLP-8 CZ-1 RPMI8226
Site of origin Pleural
effusion
Sacral
plasmacytoma
Pleural
effusion
Pleural
effusion
Peripheral
blood
Peripheral
blood
Peripheral
blood
Peripheral
blood
Bone marrow or
peripheral blood
Peripheral
blood
Gender XY XX XX XX XY XX XX XY XY XY
Ig type IgG lambda IgG kappa Ig-non-
producing
IgA kappa IgE lambda IgG lambda IgG lambda IgD lambda Light chain lambda IgG lambda
Ploidy Hypodiploid Hypodiploid Hypodiploid Hypodiploid Hypodiploid Near-tetraploid Near-tetraploid Near-diploid Hyperdiploid Hyperdiploid
Known IgH
translocation
Nil t(8;14)
(q24;q32)
t(11;14)
(q13;q32)
t(4;14)
(p16.3;q32.3)
Nil t(4;14)
(p16.3;q32.3)
t(4;14)
(p16.3;q32.3)
t(11;14)
(q13;q32)
Nil t(1;14)
(p13;q32)
Chromosome
13 status
−13 −13 del(13)(q11) −13 −13 −13 Nil Nil Nil −13
TP53 status −17; wild-
type
Homozygous
deletion
Wild-type Not known Mutated Mutated Mutated Not known i(17q) Mutated
Reference [11,12]
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Figure 5 Interphase fluorescence in situ hybridization (FISH)
analysis of the MMLAL cells. FISH with TP53 locus-specific (red)
and chromosome 17 centromeric (green) probes indicates loss of
TP53 due to monosomy 17 (arrow) and deletion 17p (arrowhead) in
different nucleated cells.
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which were able to proliferate at a higher cell density.
While continual growing of cells has been observed after
subculture with a lower cell density (data not shown),
the MMLAL might be more dependent on fresh nutrient
compounds or less tolerate to metabolic waste accumu-
lated in the culture medium, than other common used
myeloma cell lines. Hence, the MMLAL cells require
more frequent subculture in routine culture.
Bortezomib has been widely used in the treatment of
both newly diagnosed and relapsed myeloma, but drug
resistance emerges as a challenge, in particular, for
retreatment of relapsed myeloma [16,17]. While the IC50
of the MMLAL cells against bortezomib was found to beFigure 6 Characterization of the MMLAL cells. A) Cells were seeded at
medium change on every three days. The cells were stained by trypan blu
indicated. B) Cell viability of was measured by MTT assay after treatment w
untreated control. Data were plotted by the average of three independentcomparable to other bortezomib-resistant cell lines,
which showed a resistive IC50 ranging from 50nM to
150nM, the MMLAL is considered to be bortezomib-
resistant [18,19]. Therefore, the MMLAL may also serve
as a model for elucidating the mechanism of drug resist-
ance, or validating novel agents or approaches which
may overcome the resistance.
Lastly, in addition to the lower incidence of myeloma
in Chinese, there were suggestions that Chinese mye-
loma patients might have different profile of presenting
symptoms, side-effects or outcome [2,20-22]. Therefore,
availability of an additional Chinese myeloma cell line
would be conducive to future mechanistic studies in case
disparities in clinical presentation or outcome are veri-
fied in collaborative studies in Asia.
Conclusion
A new Chinese-derived human myeloma cell line, char-
acterized by hypodiploid karyotype with del(13) and loss
or del(17p), was developed.
Methods
Clinical history
A 73-year-old man presented with severe back pain and
renal failure in Dec 2009. Subsequent work-up showed
that he had International stage III IgG/lambda myeloma
with hypercalcemia (serum calcium: 3.89μmol/L; nor-
mal < 2.55μmol/L), multiple collapses in thoracic and
lumbar vertebrae in addition to rib fractures, anemia
(hemoglobin: 9.5 g/dL; normal > 11.5 g/L) and renal
impairment (serum creatinine: 333 μmol/L; normal
<110 μmol/L). Serum IgG measured 6510 mg/dL (normal
819-1725 mmol/L) with an IgG paraprotein of 48.9 g/L.
He received melphalan, prednisolone and thalidomide
achieving a complete remission in Mar 2010 but relapsed
in Sep 2010 when MPT was resumed with minimalan initial density of 1 × 106 cells/ml and allowed to grow with fresh
e and the number of viable cells measured by haemocytometer as
ith different concentrations of bortezomib, and compared to the
experiments ± standard deviations.
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one since June 2011 with partial response. However, he
was admitted in Dec 2011 because of left pleural effusion
presenting with dyspnea. Therapeutic pleural aspiration
was performed, which revealed exudative effusion with
exclusively plasma cells. Moreover, chest X-ray showed a
large left pleural mass (Figure 1). Chemical pleurodesis
was performed, and the patient expired in Jan 2012 due to
progressive myeloma. The study has been approved by
Institutional Review Board of Queen Mary Hospital, and
written informed consent has been obtained.
Cell culture
Patient mononuclear cells were isolated by gradient
centrifugation using Ficoll-Paque PLUS (GE Healthcare,
Uppsala, Sweden), according to the manufacturer’s protocol.
Initially, cells were maintained in a medium mixture
of 40% DMEM + 40% IMDM, supplemented with 20%
fetal bovine serum and 10 ng/ml IL-6 (R&D Systems,
Minneapolis, MN, USA). When cell number started to
increase, cells were gradually maintained in the medium
mixture without IL-6. Medium change was done every 3
or 4 days. All media contained penicillin and strepto-
mycin. All cells were incubated in a humidified atmos-
phere of 5% CO2 at 37°C. All cell culture reagents were
obtained from Invitrogen (Carlsbad, CA, USA).
Other human myeloma cell lines included KMS-12-
PE, NCI-H929, and JJN-3. KMS-12-PE was purchased
from Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DSMZ) (Braunschweig, Germany).
NCI-H929 was purchased from American Type Culture
Collection (ATCC) (Manassas, VA, USA). JJN-3 was kindly
provided by Dr. Wee Joo Chng (Department of Medicine,
National University of Singapore). Cell lines were main-
tained in RPMI medium 1640, supplemented with 10-20%
fetal bovine serum.
Immunophenotypic analysis
For immunophenotyping of MMLAL cells, cells were
stained with anti-CD38 (LSI19843), anti-CD138 (B-
A38) (Beckman Coulter, Fullerton, USA), and anti-IgG,
kappa, lambda (polyclonal) (DakoCytomation, Glostrup,
Denmark). In most cases 1 × 104 cells were analysed.
CD138 + CD38 + CD56- cells were defined as plasma
cells. Cells were acquired by FC 500 using CXP 2.2 soft-
ware (Beckman Coulter).
Cytogenetic analysis
Cell culture was fed with fresh growth medium 24 hours
prior to harvest for cytogenetic study. The cells were
treated with colcemid at a final concentration of 0.1 ug/
mL for 1 hour at 37°C. Details of the cytogenetic tech-
niques and slides preparation for chromosome examin-
ation were previously reported [23]. Briefly, air-dried slideswere prepared following hypotonic treatment (0.075 M
KCl) and acetic/methanol (1:3 v/v) fixation. Prior to band-
ing, the slides were heated at 60°C overnight and put in
7.5% H2O2 for 3 minutes. Metaphase chromosome prepar-
ation was G-banded by 0.05% trypsin and stained with
Leishman’s stain for 3 minutes. A minimum of 20 con-
secutive metaphases from each cell culture were fully ana-
lyzed. Metaphases were captured and karyotyped in Ikaros
automated karyotyping system (MetaSystems, Germany).
The karyotypes of each metaphase were described accord-
ing to the International System for Human Cytogenetic
Nomenclature [24].
Interphase fluorescence in situ hybridization (FISH)
FISH was performed on slides for the examination of
chromosome 13q deletions, t(4;14) and TP53 deletion by
using Vysis LSI D13S319 DNA probe (13q14.3), Vysis
LSI IGH/FGFR3 dual color dual fusion DNA trans-
location probe and Vysis LSI TP53/CEP 17 DNA probe
(Abbott Molecular, IL, USA) respectively. Interphase
FISH was performed on Carnoy’s fixative fixed cells
according to the manufacturer’s instructions. Briefly,
pre-digestion of cells on each slide was carried out in
0.05% pepsin (Sigma-Aldrich, MO, USA) in 0.01 M HCl.
Subsequently, slide and probes were co-denatured by in-
cubation at 72°C for 2 min on HYBrite hybridization
system (Abbott Molecular). After incubating overnight
in a dark humidity chamber at 37°C, the slide was post-
hybridization washings for 2 min in 0.4x SSC/0.3% NP40
at 73°C and 30 sec in 2X SSC/0.1% NP40 at room
temperature. The slide was mounted in DAPI II (Abbott
Molecular, IL, USA), which contained p-phenylenediamine
dihydrochloride (DAPI) as counter-stain. Subsequent image
acquisition was performed using Isis FISH imaging system
(MetaSystems, Germany). 200 cells were scored for the
hybridization signal patterns.
TP53 mutation analysis
Direct sequencing analysis of exons 4–10 of TP53 en-
ables detection of most of the known TP53 mutations
[25]. Genomic DNA extracted from MMLAL cells was
amplified by PCR using primer sets specific to these
exons, followed by bidirectional direct sequencing. Pri-
mer sets and reaction conditions were based on The
International Agency for Research on Cancer (IARC)
TP53 database (www-p53.iarc.fr) [26]. Results were com-
pared to reference sequence NM_000546.
Cell growth
Cells of 1 x 106 were cultured with 1 ml medium in a
12-well plate, with medium change in every 3 days. The
number of viable cells was recorded by trypan blue
staining in every 3 days using a haemocytometer. Data
from three independent experiments were plotted.
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Drug resistance against bortezomib, a frontline chemother-
apeutic agent for the treatment of myeloma, was measured
by 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide (MTT) assay. Briefly, cells were cultured with bor-
tezomib of different concentrations, ranging from 1.0 μM
to 0, for 48 hours in a 96-well plate. Each well was added
with 10 μl of 5 mg/ml yellowish MTT reagent for further
incubation of 4 hours, followed by addition of 100 μl of
DMSO for purple formazan solubilization. Absorbance at
550 nm with reference to 650 nm was measured using an
Epoch microplate spectrophotometer (Bio-Tek, Winooski,
VT). After blank subtraction, result of each bortezomib
concentration was obtained from average of triplicate wells
and compared with that of untreated control. Data from
three independent experiments with triplicate in each were
plotted.
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